1

2	Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19:
3	A Complementary Approach to Population Surveys
4	
5	Hassan Alkharaan <sup>1#</sup> , Shaghayegh Bayati <sup>5#</sup> , Cecilia Hellström <sup>5</sup> , Annika Olsson <sup>2</sup> , Karin
6	Lindahl <sup>2,4</sup> , Gordana Bogdanovic <sup>3</sup> , Soo Aleman <sup>2,4</sup> , Georgios Tsilingaridis <sup>1</sup> , Patricia De
7	Palma <sup>1</sup> , Sophia Hober <sup>6</sup> , Anna Månberg <sup>5</sup> , Peter Nilsson <sup>5</sup> , Elisa Pin <sup>5#</sup> , Margaret
8	Sällberg Chen <sup>1#</sup>
9	
10	<sup>1</sup> Karolinska Institutet, Department of Dental Medicine, 14152, Stockholm, Sweden
11	<sup>2</sup> Karolinska University Hospital, Department of Infectious Diseases, 14186,
12	Stockholm, Sweden
13	<sup>3</sup> Karolinska University Hospital, Department of Clinical Microbiology, 14186,
14	Stockholm, Sweden
15	<sup>4</sup> Karolinska Institutet, Department of Medicine, 14186, Stockholm, Sweden
16	<sup>5</sup> Division of Affinity Proteomics, Department of Protein Science, School of
17	Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal
18	Institute of Technology, SciLifeLab, Stockholm, Sweden
19	<sup>6</sup> Division of Protein Technology, Department of Protein Science, KTH Royal Institute
20	of Technology, Stockholm, Sweden
21	
22	#These authors contributed equally
23	
24	Running title: Salivary IgG to SARS-CoV-2 After Mild COVID-19
25	Corresponding author: Professor Margaret Sällberg Chen
26	Word count: 198 (abstract) 3487 (total)
27	Figure and table count: 3 figures, 3 tables, 3 supplementary figures.

# 28 Footnote page

- 29
- 30 Conflict of interest statement: NO
- 31 **Financial support statement:** This study was supported by grants from Region
- 32 Stockholm, Knut and Alice Wallenberg foundation, Science for Life Laboratory
- 33 (SciLifeLab), Erling-Persson family foundation (to SH).
- 34 This study has not been presented any conference or meeting
- 35 Corresponding author contact information Professor Margaret Sällberg Chen,
- 36 Karolinska Institutet, Sweden. Email: Margaret.Chen@ki.se
- 37
- 38

## 39 Abstract

40 **Background:** Declining humoral immunity in COVID-19 patients and possibility of 41 reinfections has raised concern. Mucosal immunity particularly salivary antibodies 42 could be short-lived. However, long-term studies are sparse.

43 *Methods:* Using a multiplex bead-based array platform, we investigated antibodies 44 specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins 45 in 256 saliva samples from convalescent patients 1-9 months after symptomatic 46 COVID-19 (n=74, Cohort 1), undiagnosed individuals with self-reported 47 questionnaires (n=147, Cohort 2), and individuals sampled pre-pandemic time (n= 48 35, Cohort 3).

49 **Results:** Salivary IgG antibody responses in Cohort 1 (mainly mild COVID-19) were 50 detectable up to 9 month recovery, with high correlations between spike and 51 nucleocapsid specificity. At 9 months, IgG remained in saliva in majority as seen in 52 blood serology. Salivary IgA was rarely detected at this timepoint. In Cohort 2, 53 salivary IgG and IgA responses were significantly associated with recent history of 54 COVID-19 like symptoms. Salivary IgG also tolerated temperature and detergent pre-55 treatments.

56 **Conclusions:** Unlike SARS-CoV-2 salivary IgA that appeared short-lived, the 57 specific IgG in saliva appears stable even after mild COVID-19 as noted for blood 58 serology. The non-invasive saliva-based SARS-Cov-2 antibody testing with self-59 collection at homes may thus serve as a complementary alternative to conventional 60 blood serology.

61

62 **Keywords:** COVID-19, saliva, antibody, serology, convalescence, immunoassay

## 63 Introduction

64 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbroke 65 in an abrupt fashion since it was reported in Wuhan, China, in late December 2019 66 (1), and obligated the World Health Organization to declare a global health 67 emergency which escalated the concern to a pandemic situation on March 2020. As 68 of Mars 2021, SARS-CoV-2 had infected over 114 million cases and caused up to 69 2.5 million global deaths (2). The human adaptive immune system plays a key role to 70 eliminate and memorize infectious microbes by launching a cascade of physiological 71 activities that brings to the activation of B and T lymphocytes. B lymphocytes are 72 responsible for producing antibodies that recognize and neutralize SARS-CoV-2 73 antigens in order to eradicate the infection and have shown to play a vital role in 74 protecting against re-infections in animal and humans (3-5). IgG, IgA, and IgM 75 antibodies, all principal contributors of humoral immunity, are activated against 76 SARS-CoV-2 and detected in the circulating blood of more than 90% of infected 77 individuals from the 11-13 day post-symptom onset (PSO) (6-8). Currently, the 78 SARS-CoV-2 immunity is under extensive examinations; a recent study showed that 79 circulating antibodies post-SARS-CoV-2 infection can persist up to 8 months (9), and 80 other previous studies show this immunological memory persists for a certain period 81 followed by a slight decay, especially in asymptomatic infected individuals (10–14). 82 Oral and nasal cavities are considered the main gate for SARS-CoV-2 virus entry, 83 and saliva secretory antibodies may be the first immunity arm that combat the 84 infection by recognizing the virus. Salivary antibodies to SARS-CoV-2 can be 85 detected early after symptom onset and may persist for up to at least three months

post infection (8,10,12). Hence, saliva sampling could be a sensible and non-invasive
way to indicate SARS-CoV-2 exposure. Similar to the previous SARS-CoV and

88 MERS-CoV, the spike protein (S) of SARS-CoV-2 recognizes the angiotensin-89 converting enzyme 2 (ACE2) receptor and uses it as a key entry to attack the host 90 cells (15–17). Antibodies play an important role in resolving acute SARS-CoV-2 91 infection (11,18) but differential features of anti-SARS-CoV-2 antibodies negatively 92 impacting COVID-19 severity in hospitalized patients is also described, especially 93 related to complement deposition and systemic inflammation (19). Understanding the 94 dynamics and durability of antibody memory to SARS-CoV-2 is an instrumental step 95 to manage the pandemic, and even useful in deploying vaccination strategies. 96 However, as the mucosal immunity is known to be short-lived, the durability of SARS-97 CoV-2 specific antibodies in saliva could be limited, and whether they permit 98 detection 3-4 month after infection (8,10) is of great interest.

99 In this study, we exploited a highly sensitive and specific multiplex SARS-CoV-2 100 serology platform previously validated for seroprevalence studies (20) to investigate 101 SARS-CoV-2 antibodies in the saliva. Samples from patients with diagnosis of mild 102 coronavirus disease (COVID-19) in the convalescence phase, at 1-9 months after 103 diagnosis of COVID-19; and from undiagnosed individuals with or without history of 104 COVID-19 symptoms, were analysed and compared to pre-pandemic samples. Our 105 data indicate that spike-specific IgG reactivity is detectable in saliva in vast majority 106 of patients 1 - 9 months post infection. This result was similar to that detected by 107 blood serology performed in the clinical diagnostic laboratory. The IgA reactivity on 108 the other hand was short-lived in saliva, detectable only the first 3 months. Moreover, 109 IgG and IgA reactivity to both spike and nucleocapsid antigens significantly 110 correlated with a history of COVID-19 like symptoms in undiagnosed individuals.

111

#### 112 Materials and methods

#### 113 Experimental Design

114 We applied a bead-based serology assay to detect IgG and IgA to SARS-CoV-2 115 proteins in saliva samples to evaluate its performance. The assay method is 116 originally developed for detection of SARS-CoV-2 specific IgG in serum and plasma 117 (20). Salivary IgG and IgA responses to five different SARS-CoV-2 antigens (three 118 spike proteins and two nucleocapsid proteins) were first tested. The antigens' 119 performance in classifying positive and negative samples was evaluated for the 120 single antigens as well as for antigens combined in panels. Best performing 121 representations of spike and nucleocapsid were chosen in subsequent assessments.

122

## 123 Cohort Design

124 The study was approved by the human ethical authority (dnr 2020-01702, 2020-125 06381) and complied with the declaration of Helsinki. All participants were recruited 126 after signing informed consent forms for this observational study. Saliva samples 127 (total n=256) were collected and arranged in following groups. Cohort 1: 128 convalescence COVID-19 samples (n=74) of 72 patients (2 participants donated 129 twice at 6 months apart) diagnosed with COVID-19 during March-April 2020, were 130 collected from June to December 2020; Cohort 2: samples from undiagnosed 131 individuals donated during May-Nov 2020 (n=147); Cohort 3: anonymous saliva 132 samples were from 2018 before the COVID-19 outbreak (pre-pandemic, n=35).

All convalescent patients (Cohort 1) had COVID-19 diagnosis confirmed by SARS-CoV-2 RT-PCR, except one patient who had positive SARS-CoV-2 antibodies at four time points in the convalescence phase. Seroconversion was tested by clinical SARS-CoV-2 blood serology assays (described below). The patients were recruited

137 from the department of Infectious Diseases, Karolinska University Hospital (n=65), 138 and University Dental Clinic of Karolinska Institutet (n=7). Clinical demographic data 139 of convalescent patients was compiled from medical journal records or questionnaire, 140 and used in subgroup analysis. Among 72 patients, 95.8% had mild COVID-19, 141 without hospitalization due to COVID-19 symptoms. Three were admitted to hospital 142 for purpose of only isolation, and three were admitted due to COVID-19 symptoms. In 143 the latter group, two were hospitalized without any required oxygen treatment and 144 one received maximum 1.5 litre oxygen treatment during the hospitalization, 145 indicating no severe disease outcome. The time-points of serum and saliva samples 146 collection were grouped according to time post symptom onset (PSO), i.e. (i) PSO 147 less than 3 months. (ii) PSO of 3-8 months. (iii) PSO of 9 months. Cohort 2 148 constitutes of anonymous participants visiting the premises of University Dental Clinic 149 of Karolinska Institutet or Eastman Institute Stockholm during the study time, such as 150 patients, staff, or relatives to them. A questionnaire was used to collect COVID-19 151 related symptom information for sub-group analysis of undiagnosed samples into (i) 152 Symptomatic (ii) Non-symptomatic, based on their past 3 months health condition 153 before sampling.

154

#### 155 Saliva samples collection

Expectorated unstimulated whole saliva samples were used throughout this study. All samples were self-collected using standardized instructions and sample tubes provided by this study, processed and stored at -80 within 24 hr. Salivary stability tests were performed on samples subgroups to evaluate the antibody reactivity using samples treated with 1% Triton X-100 for 1 hour at room temperature or heat-treated at 56 C for 30 min in water bath to allow viral inactivation (19). Eighteen antibody-

positive from Cohort 1 and 10 antibody-negative samples from Cohort 2 were included in the comparison. Incubation at room temperature for one to three days was also tested in five samples to simulate the standard circumstances of mailed-in saliva self-collection procedure. Saliva samples from convalescent patients (Cohort 1) were collected on the same day as venous blood during a COVID-19 follow-up examination at the department of Infectious Diseases, Karolinska University Hospital.

168

#### 169 **Clinical serology tests**

170 Paired serum samples of all convalescent patients were tested by Dept. of Karolinska 171 University Hospital Clinical Microbiology Laboratory. Three automated and one in-172 house diagnostic methods were used under the study period of included 173 convalescence blood samples - SARS-CoV2-IgG test iFlash 1800 YHLO (CLIA), 174 LIAISON® SARS-CoV-2 S1/S2 IgG test DiaSorin (CLIA), and SARS CoV-2 IgG in-175 house ELISA for samples taken prior to June 2020 mainly early convalescence 176 samples (<9month). The Elecsys® Anti-SARS-CoV-2 antibody test Roche (ECLIA) 177 was used for all late convalescence samples (9-month). YHLO determines the 178 antibodies against SARS-CoV-2 nucleocapsid and spike protein, DiaSorin against 179 spike protein, whilst Elecsys<sup>®</sup>, and in-house ELISA to the recombinant nucleocapsid 180 tests use different techniques such as chemiluminescence protein. The 181 immunoassay (CLIA), electrochemiluminescence immunoassay (ECLIA), and 182 enzyme-linked immunoassay (ELISA).

183

# 184 Antigen Production

185 The proteins were produced as following: 1) Spike-f as spike trimers comprises the 186 prefusion-stabilized spike glycoprotein ectodomain is expressed in HEK cells and

purified using a C-terminal Strep II tag, 2) Spike S1 domain was expressed in CHO cells and purified using C-terminal HPC4-tag, 3) Spike RBD domain was expressed in HEK cells and purified using the mFc C tag; 4) nucleocapsid, one full-length version and 5) one nucleocapsid C-terminal chain were each expressed in *E.coli* and purified using a C-terminal His-tag (21,22).

192

#### 193 SARS-CoV-2 antibody detection by a bead-based assay

194 The analysis of salivary antibodies was performed as previously described (20) with 195 a few modifications. Briefly, each antigen was diluted to a final concentration of 80 196 µg/ml (100mM) with 2-(N-morpholino) ethanesulfonic acid buffer, pH 4.5 197 (SigmaAldrich) and immobilized on uniquely color-coded bead type (bead ID) 198 (MagPlex-C, Luminex corp.). The antigen-immobilized beads were then pooled to 199 form the bead array. Besides the viral antigens, anti-human IgG (309-005-082, 200 Jackson Immunoresearch), anti-human IgA (800-338-9579, Bethyl), and the EBV 201 EBNA1 protein (ab138345, Abcam) were also included as sample loading controls.

202 Saliva samples were diluted 1/5 in assay buffer composed of 3% bovine serum 203 albumin (w/v), 5% non-fat milk (w/v) in 1×PBS supplemented with 0.05 % (v/v) 204 Tween20 (VWR, 437082Q) and incubated with the bead array for 1 hour at room 205 temperature and 650 RPM rotation. Afterwards, the antigen-antibody complexes 206 were cross-linked by adding 0.2% paraformaldehyde (AlfaAesar, 30525-89-4) in PBS 207 0.05% Tween 20 (PBS-T) for 10 min at room temperature. Detection was performed 208 by applying R-phycoerithryne-conjugated anti-human IgG (H10104, Invitrogen) 209 diluted 0.4 µg/mL, or R-phycoerithryne-conjugated anti-human IgA (800-338-9579, 210 Bethyl) diluted 0.2 µg/mL in PBS-T for 30 minutes at room temperature. Finally, the

211 read-out was performed by using a FlexMap3D system and the xPONENT software

212 (Luminex Corp.).

#### 213 Statistical analysis.

214 Statistics and visualizations of the multiplex bead array generated data were 215 performed using R (version 3.6.1) with RStudio (version1.2.1335) and the additional 216 packages heatmap (1.0.10), reshape2 (1.4.3). In-house developed functions were 217 used for instrument file import and quality control. The bead array results were 218 acquired as Median Fluorescent Intensity (MFI) per sample and bead identity. A 219 cutoff for seropositivity was calculated per antigen as the mean + 7x SD of 12 220 negative pre-pandemic reference samples carefully selected based on their signal 221 intensity distribution. GraphPad Prism Version 9.0.0 (86) was used for the 222 nonparametric comparisons Mann-Whitney test and Spearman correlation analysis. 223 Datasets also initially underwent normality distribution testing. N1 Chi-squared test 224 was used for comparisons of binomial datasets in MedCal software calculator. Two-225 sided p-values <0.05 were considered significant. Descriptive analyses were made 226 on clinical characteristics and the number of observations, presented as numbers 227 and percentages.

#### 228 **Results**

#### 229 Salivary antibody reactivity to SARS-CoV-2 proteins

The assay performance was validated by comparing the capability of each of the five antigens included in the array to classify convalescent samples <3 mo–9 mo (Cohort 1, n=74) and pre-pandemic samples (Cohort 3, n=35), of which 12 samples from Cohort 3 were used to set the assay cut-offs. Among the five antigens included in the assay, spike foldon (Spike-f) and C-terminal fragment (NC-C) showed the best

235 performance (88% and 61% sensitivity respectively, and 100% specificity) in 236 classifying SARS-CoV-2 saliva samples of the convalescence cohort from the pre-237 pandemic cohort (Table 1). We also evaluated the antigen panel in all possible 238 combinations of 2 and 3 proteins, considering as *positive* a sample that showed 239 reactivity to both antigens in a panel-of-two antigens, and at least to two out of three 240 antigens in a panel-of-three antigens (**Table S1 and 2**). There, the best performance 241 among the panels was reached by the Spike-f, S1, RBD triple combination, showing 242 70.3% sensitivity and 100% specificity. Hence, the absolute best performance was 243 shown to be reached by Spike-f as single antigen (88% sensitivity, 100% specificity) 244 in this COVID-19 convalescent and pre-pandemic saliva collection. IgA reactivities to 245 the included proteins were identified only in a minority of cases, with higher 246 prevalence of reactivity to Spike-f (12%) (Table S3).

247

#### 248 Serum and salivary antibody reactivity overtime post Covid-19

249 As shown in **Table 2**, Cohort 1 were mainly patients who have had mild COVID-19 250 and were grouped according to duration past their diagnosis. Some were hospitalized 251 for isolation mainly, but none received oxygen treatment or required ventilation 252 related treatment. All individuals were free from respiratory symptoms at the 9-month 253 follow-up but in a minority across all three groups various general residual symptoms 254 were still noted (data not shown). As shown in **Table 3**, the vast majority of serum 255 samples up to 9 months convalescence were still tested positive in clinical SARS-256 CoV-2 serology, with high seroprevalence across the whole time span of collection. 257 Interestingly, paired saliva samples from Cohort 1 patients tested with the multiplex 258 bead-array showed that the positivity rate of anti-Spike-f IgG in saliva remained 259 remarkably high and in similar range (100%-87.5%) as noted for serum antibodies

(88.9%-96.9) throughout from early (<3 months) to late convalescence group (9 months) (**Table 3, Figure 1a**). However, the NC-C specific IgG in saliva dropped significantly after 3 months (from 88.9% to 60.6-50.0%). As stated earlier, specific IgA responses to these antigens were detected only in a minority of the saliva samples, and was enriched in early convalescence (<3months, 44.4% for Spike-f and 11% for NC-C), while dropping to less than 10% in later convalescent samples (p<0.01).</p>

Moreover, salivary IgG to Spike-f and NC-C showed to be highly correlated in this cohort (r=0.88, p<0.0001, Spearman correlation test), with concordant serostatus in the majority of samples (**Figure 1b**). Significant albeit moderate correlations were also seen between IgA to Spike-f and NC-C (r=0.62, p<0.001), and between Spike-f specific IgA and IgG (r=0.45, p<0.001) (Figure 1b).

272

Salivary antibody reactivity to SARS-CoV-2 in healthy donors is associated with the
recent history of COVID-19 like symptoms.

275 Next, we applied this assay platform to evaluate a second independent cohort -276 Cohort 2. Participants here were self-reporting symptom-free individuals visiting the 277 University Dental Clinic's premises of Karolinska Institutet and the Eastman Institute 278 in Stockholm. A total of 147 individuals from May to November 2020 participated in 279 and donated saliva samples. Samples were collected and tested using the same 280 standard operating protocol as for Cohort 1. Shown in Figure 2a, and based on 281 antigen-specific cutoffs calculated on 20 negative controls, antibody reactivities to 282 Spike-f and NC-C in this cohort were as following: IgG were detected in 14% to either 283 Spike-f or NC-C, while 11% had detectable IgG to both antigens; for IgA, 10% and 284 6% of the samples showed reactivity to Spike-f and NC-C respectively, while only 5%

285 showed reactivity to both. Salivary positivity was particularly enriched among 286 participants with self-reported recent history of COVID-19-like symptoms (14 days to 287 3 months prior to sampling time). Significant reactivities of IgG (p=0.004, and p=0.01) 288 and IgA (p<0.0001, and p=0.044) to either Spike-f or NC-C was found to associate 289 with recent history of symptoms compared to pre-pandemic controls (Figure 2a). 290 A correlation analysis (Figure 2b) gave similar result as for Cohort 1, with highest 291 reported correlation between salivary IgG to Spike-f and NC-C (r=0.81, p<0.0001, 292 Spearman correlation test). Significant albeit moderate correlations were also seen 293 between IgA to Spike-f and NC-C (r=0.73, p<0.001), and IgG and IgA to Spike-f 294 (r=0.49, p<0.001), and Spike-f IgA to NC-C IgG (r=0.53, p<0.001).

295

Saliva antibody stability – the influence of inactivation pre-treatment and room
 temperature

298 Next the effects of inactivation treatment with 1% Triton X-100 or heat-treatment at 299 56 C, as well as room temperature storage (identical aliquots left out for indicated 300 time) on the antibody results were determined (Figure 3). Both 1% Triton X-100 and 301 heat treatment showed slight or no change in the cutoff calculated based on the ten 302 included negative controls. A good correlation between treated and non-treated 303 samples was noted (Figure 3 and S1), with a few exceptions of single samples that 304 show a drop in IgG reactivity. Simulation with room temperature storage (22°C) 305 showed a slow decay in IgG signal intensity in positive samples (blue) over time, with 306 the signals of negative samples remain low and stable (grey). Based on these data, 307 inactivation by Triton X-100 or heat treatment treatments seems to have little effect 308 on saliva samples. However, antibody decay variations showed slight IgG signal 309 reduction by each day of room temperature storage.

## 310 **Discussion**

311 Comprehensive antibody testing and the subsequent interventions they generate are 312 essential to monitoring and control SARS-CoV-2 transmission. The present study 313 demonstrates that SARS-CoV-2 specific IgG in saliva after mild COVID-19 can serve 314 as a complementary measure of exposure or immunity to SARS-CoV-2, particularly 315 due to their frequent concurrence with serum IgG responses. Key findings include 1) 316 SARS-CoV-2-specific mucosal salivary antibodies co-exist with the circulating blood 317 antibodies up to 9 months post-natural infection in the majority of participants (88% in 318 saliva vs. 97% in blood); 2) natural infection induces salivary antibodies to recognize 319 both viral spike and nucleocapsid proteins; 3) the response correlates significantly to 320 recent Covid-19-like symptom history in undiagnosed individuals; 4) saliva IgG is 321 relatively stable tolerating both biosafety required temperature and detergent pre-322 treatment. All together representing a non-invasive approach suitable for population-323 based immunity surveys. Ideally, if the latter is sampled at home and mailed to the 324 lab, it can help protect vulnerable persons at risk for severe COVID-19 by sparing the 325 need to visit the laboratory units for blood drawls. This is an appealing way to test 326 persons, in pandemic situation, and definitely a complementary test for conventional 327 blood IgG assay. Our data also showed that sample inactivation with either heat 328 treatment or Triton X-100 might be both safe options for testing saliva sample in the 329 lab, causing very little to no variation on the assay performance.

330

331 Severe COVID-19 symptoms have been shown to cause strong antibody responses 332 in 99% of convalescence individuals, but published data show also that the antibody 333 responses tend to disappear faster in cases with mild symptoms (6, 9, 16, 19). 334 Possible reason for this is that tests developed earlier during the pandemic were

based on detection in samples from severe COVID-19 cases rather than individuals 335 336 with mild symptoms, hence sensitivity was not optimal (23). Further, many of the 337 early developed tests are using the nucleocapsid as antigen and antibodies targeting 338 this part of the virus has been shown to decline faster (24) as also was detected 339 here. In this study, we deliberately recruited convalescence samples from mild 340 COVID-19 patients, showing that the multiplex antibody platform used here was 341 capable of detecting specific SARS-CoV-2 antibodies in saliva up to 9 months post 342 infection. In the present study, the clinical blood test results that were compared with 343 the saliva reactivities are from certified patient diagnostics (including anti-N pan-Ig 344 ECLIA), showed high performance in detecting late convalescence blood samples. In 345 fact, our result is in line with a recent South Korean group reporting this diagnostic 346 antibody assay is, among several others, effective in detecting SARS-CoV-2 347 antibodies in blood (90%) of individuals up to 8 months after either asymptomatic 348 infection or reporting mild-symptoms (25). The persistence of salivary IgG to 349 structural viral proteins in the saliva samples after 9 months recovery from mild 350 COVID-19 is intriguing, and possibly explained by a secondary exposure or spill-over 351 from the blood. More studies are therefore warranted to clarify this. In relation to it, 352 the mucosal antibody response is triggered slightly earlier upon infection (10). 353 Information is still limited about the duration and kinetics of mucosal antibodies 354 secreted into the mouth and nose, particularly in this patient group. A sensitive 355 salivary antibody detection assay with the capability to identify infections with various 356 severities would contribute to improving the current understanding of mucosal 357 antibodies to SARS-CoV-2. For instance, such studies may compare low versus high 358 avidity antibodies and their relation to neutralization or disease enhancement 359 (10, 26, 27).

360

361 The notion that antibodies to previously known coronaviruses may block SARS-CoV-362 2 has raised a concern about whether these antibodies are functional. However, such 363 antibodies are also known to be protective only for about 6 months after the infection, 364 therefore would have disappeared in most cases of SARS-CoV-2 (28,29), Comparing 365 saliva samples using pseudo-neutralizing assay in ACE-2 cross-blocking 366 experiments will therefore be interesting. Other applications for quantitative and 367 qualitative saliva antibody assays include immunity studies to elucidate vaccine-368 induced mucosal immunity, including the response to antigens representing new 369 virus mutants and vaccine-induced escape mutants. Since mouth and nose are the 370 first port of entry for SARS-CoV-2, sensitive and accurate methods for quantitative 371 measurements of such local mucosal immunity will lead to better means to combat 372 this virus.

373

374 One limitation of our study was the relatively small sample size and the 375 predominantly male population. Another weakness is blood samples were not 376 analyzed same way as saliva, and as several diagnostic assays were used only 377 binary data is given. Also, because of the cross-sectional design, we could not obtain 378 baseline or longitudinal saliva samples. Moreover, we could not assess individual 379 possibilities of re-exposure or re-infection. However, it is unlikely that humoral 380 immunity was boosted because in Stockholm, where the study takes place, the 381 period June-Nov 2020 (second-wave) showed an increase in the daily incidence rate 382 of COVID-19 from 30 to 400 cases/100,000 population (30). In conclusion, despite 383 waning immunity concerns, the present study shows how our multiplex bead-based

- immunoassays can detect antibodies against SARS-CoV-2 in saliva collected at 9
- 385 months after infection in the majority of mildly symptomatic persons.
- 386
- 387 Authors contributions: E.P., A.M., P.N., M.S.C. conception and design of the study.
- 388 H.A., S.B., A.M., A.O., collected the material and performed the experiments. H.A.,
- 389 S.B., C.H. A.M., E.P., M.S.C. analyzed the data. E.P., AM, P.N., and M.S.C.
- 390 supervised the work. K.L., S.A. G.B. S.H. contributed with material and data
- interpretations, H.A., S.B., E.P., and M.S.C. wrote the manuscript. All authors
- 392 reviewed and revised the manuscript critically.
- 393

## 394 Acknowledgments

395 All study participants who took interest in this study.

# 396 **References:**

397	1.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus
398		from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-
399		33.
400	2.	University of Johns Hopkins. Coronavirus Resource Center [Internet]. Available
401		from: https://coronavirus.jhu.edu/map.html
402	3.	Krammer F. SARS-CoV-2 vaccines in development. Nature [Internet]. 2020 Oct
403		22;586(7830):516-27. Available from: http://dx.doi.org/10.1038/s41586-020-
404		2798-3
405	4.	Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of
406		an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against
407		SARS-CoV-2. Cell. 2020;182(3):713-721.e9.
408	5.	Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et
409		al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care
410		Workers. N Engl J Med [Internet]. 2021 Feb 11;384(6):533-40. Available from:
411		http://www.nejm.org/doi/10.1056/NEJMoa2034545
412	6.	Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V,
413		McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion
414		in humans. Nat Med [Internet]. 2020;26(7):1033–6. Available from:
415		http://dx.doi.org/10.1038/s41591-020-0913-5
416	7.	Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann
417		AJ, et al. The receptor-binding domain of the viral spike protein is an
418		immunodominant and highly specific target of antibodies in SARS-CoV-2
419		patients. Sci Immunol. 2020;5(48):1–10.
420	8.	Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody

421 responses to SARS-CoV-2 in patients with COVID-19. Nat Med.

422 2020;26(6):845–8.

- 423 9. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological
- 424 memory to SARS-CoV-2 assessed for up to 8 months after infection. Science
- 425 (80-) [Internet]. 2021 Feb 5;371(6529):eabf4063. Available from:
- 426 https://www.sciencemag.org/lookup/doi/10.1126/science.abf4063
- 10. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of
- 428 serum and saliva antibody responses to SARS-CoV-2 spike antigens in
- 429 COVID-19 patients. Sci Immunol. 2020;5(52):1–21.
- 430 11. Baumgarth N, Nikolich-Žugich J, Lee FE-H, Bhattacharya D. Antibody
- 431 Responses to SARS-CoV-2: Let's Stick to Known Knowns. J Immunol

432 [Internet]. 2020 Nov 1;205(9):2342–50. Available from:

433 http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.2000839

- 434 12. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et
- 435 al. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody
- 436 Responses in Saliva. Loeffelholz MJ, editor. J Clin Microbiol [Internet]. 2020
- 437 Dec 17;59(1):1–13. Available from: https://jcm.asm.org/content/59/1/e02204-20
- 438 13. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et
- 439 al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-
- 440 Prevalence Communities and Reveal Durable Humoral Immunity. Immunity
- 441 [Internet]. 2020 Nov;53(5):925–933.e4. Available from:
- 442 https://linkinghub.elsevier.com/retrieve/pii/S1074761320304453
- 14. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and
- 444 immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med
- 445 [Internet]. 2020 Aug 18;26(8):1200–4. Available from:

446		http://www.nature.com/articles/s41591-020-0965-6
447	15.	Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, et al. Cryo-electron
448		microscopy structures of the SARS-CoV spike glycoprotein reveal a
449		prerequisite conformational state for receptor binding. Cell Res [Internet]. 2017
450		Jan 23;27(1):119–29. Available from: http://www.nature.com/articles/cr2016152
451	16.	Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et
452		al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked
453		by a Clinically Proven Protease Inhibitor. Cell [Internet]. 2020 Apr;181(2):271-
454		280.e8. Available from:
455		https://linkinghub.elsevier.com/retrieve/pii/S0092867420302294
456	17.	Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-
457		converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature
458		[Internet]. 2003 Nov;426(6965):450–4. Available from:
459		https://doi.org/10.1038/nature02145
460	18.	Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM,
461		Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute
462		COVID-19 and Associations with Age and Disease Severity. Cell [Internet].
463		2020;183(4):996–1012.e19. Available from:
464		https://doi.org/10.1016/j.cell.2020.09.038
465	19.	Opeyemi S. Adeniji1, Leila B. Giron1, Netanel F Zilberstein,2 Maliha
466		W.Shaikh2, Robert A Balk2, James N Moy2, Christopher B. Forsyth2, Ali
467		Keshavarzian2, Alan 10 Landay2 MA-M. COVID-19 Severity Is Associated with
468		Differential Antibody Fc-mediated Innate Immune Functions. bioRxiv Prepr
469		[Internet]. 2021; Available from:
470		https://www.biorxiv.org/content/10.1101/2021.01.11.426209v1?s=09

- 471 20. Rudberg A-S, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et
- 472 al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare
- 473 workers in Sweden. Nat Commun [Internet]. 2020 Dec 8;11(1):5064. Available
- 474 from: http://www.nature.com/articles/s41467-020-18848-0
- 475 21. Tegel H, Steen J, Konrad A, Nikdin H, Pettersson K, Stenvall M, et al. High-
- throughput protein production Lessons from scaling up from 10 to 288
- 477 recombinant proteins per week. Biotechnol J [Internet]. 2009 Jan;4(1):51–7.
- 478 Available from: http://doi.wiley.com/10.1002/biot.200800183
- 479 22. Kanje S, Enstedt H, Dannemeyer M, Uhlén M, Hober S, Tegel H.
- 480 Improvements of a high-throughput protein purification process using a
- 481 calcium-dependent setup. Protein Expr Purif [Internet]. 2020
- 482 Nov;175(June):105698. Available from:
- 483 https://doi.org/10.1016/j.pep.2020.105698
- 484 23. Takahashi S, Greenhouse B, Rodríguez-Barraquer I. Are Seroprevalence
- 485 Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? J
- 486 Infect Dis [Internet]. 2020 Nov 9;222(11):1772–5. Available from:
- 487 https://academic.oup.com/jid/article/222/11/1772/5898481
- 488 24. Havervall S, Jernbom Falk A, Klingström J, Ng H, Greilert-Norin N, Gabrielsson
- 489 L, et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity
- 490 after asymptomatic to mild COVID-19 infection. medRxiv [Internet].
- 491 2021;2021.01.03.21249162. Available from:
- 492 https://doi.org/10.1101/2021.01.03.21249162
- 493 25. Choe PG, Kim K-H, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody
- 494 Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection.
- 495 Emerg Infect Dis [Internet]. 2021 Mar;27(3):928–31. Available from:

|--|

- 497 26. Wen J, Cheng Y, Ling R, Dai Y, Huang B, Huang W, et al. Antibody-dependent
- 498 enhancement of coronavirus. Int J Infect Dis [Internet]. 2020 Nov;100:483–9.
- 499 Available from: https://doi.org/10.1016/j.ijid.2020.09.015
- 500 27. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent
- 501 enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol
- 502 [Internet]. 2020 Oct 9;5(10):1185–91. Available from:
- 503 http://dx.doi.org/10.1038/s41564-020-00789-5
- 28. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al.
- 505 Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
- 506 antibody. Nature [Internet]. 2020;583(7815):290–5. Available from:
- 507 http://dx.doi.org/10.1038/s41586-020-2349-y
- 508 29. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al.
- 509 Seasonal coronavirus protective immunity is short-lasting. Nat Med [Internet].
- 510 2020;26(11):1691–3. Available from: http://dx.doi.org/10.1038/s41591-020-
- 511 1083-1
- 512 30. Folkhälsomyndighetens. Folkhälsomyndighetens veckorapporter om covid-19.
- 513 [Internet]. 2020. p. June-November. Available from:
- 514 https://www.folkhalsomyndigheten.se/folkhalsorappo
- 515

## 516 **Figure legends**

**Figure 1**. Measurement of IgG and IgA to Spike-f (soluble trimeric form of the spike glycoprotein stabilized in the pre-fusion conformation) and NC-C (nucleocapsid Cterminal fragment) of SARS-CoV2 in saliva of convalescence patients (Cohort 1). (A) Multiplex assay measured signal scores on indicated immunoglobulins to Spike-f and 521 NC-C in cohorts of pre-COVID samples (n=35), and convalescent patient samples at 522 indicated month post infection (n=74). The data is expressed in median fluorescence 523 index (MFI) and plotted using dot plots where each dot is one individual sample. 524 Horizontal bars denote the mean and vertical line represents standard errors. Mann-525 Whitney U test for significance was performed (B) Spearman correlation analysis with 526 coefficient indicated for respective antibody specificity pairs. n.s = not significant.

527

528 Figure 2. SARS-CoV2 specific IgG and IgA in saliva of undiagnosed study 529 participants (Cohort 2) measured by same method as in Figure 1. Samples were sub-530 grouped by participant reported COVID-like symptoms the past 14 days - 3 months 531 prior to sampling (Cohort 2). (A) Multiplex assay measured signal scores on indicated 532 immunoglobulins to Spike-f and NC-C in cohorts of pre-COVID samples (n=35), and 533 convalescent patient samples at indicated month post infection (n=146). The data is 534 expressed in median fluorescence index (MFI) and plotted using dot plots where 535 each dot is one individual sample. Horizontal bars denote the mean and vertical line 536 represents standard errors. Mann-Whitney U test for significance was performed (B) 537 Spearman correlation analysis with coefficient indicated for respective antibody 538 specificity pairs. n.s = not significant.

539

**Figure 3.** Stability tests of saliva samples subjected to heat (HT), 1% Triton-X-100 (Triton), or left for indicated time in room temperature. (A) SARS-CoV2 specific IgG and IgA reactivities in convalescence saliva samples (Pos) or Pre-pandemic saliva samples (Neg) were tested either untreated (Untreated) or after heat inactivation at 56°C for 30 min (HT), or after Triton-X-100 inactivation (final 1% volume/volume) for 60 min (Triton). Reactivities to Spike-f respective NC-C antigens are shown as box

plots with each dot representing one single sample. (B) Convalescence saliva samples (blue) or pre-pandemic saliva samples (grey) were aliquoted and placed in room temperature (22°C) at indicated time points, thereafter snap frozen and tested in same assay run for measurement of SARS-CoV2 specific IgG to spike or nucleocapsid.

551

## 552 Supplementary materials

- 553 Figure S1. Correlation analysis comparing inactivation by heat, Triton-X-100, and
- 554 untreated conditions as shown in Figure 3A.

		Convalescent (N=74)			4) <b>Pre-pandemic</b> (N=23) <sup>#</sup>		
Antigen	Host	Sensitivity [%]	Pos	Neg	Specificity [%]	Pos	Neg
Spike-f	HEK	88	65	9	100	0	23
S1	СНО	61	45	29	100	0	23
RBD	HEK	69	51	23	96	1	22
NC	E. coli	49	36	38	100	0	23
NC-C	E. coli	61	45	29	100	0	23

# Table 1. Single antigen specificity and sensitivity in detecting SARS-CoV-2 IgG in convalescent saliva (1-9 month PSO) and pre-pandemic saliva samples.

<sup>#</sup>Another 12 independent pre-pandemic saliva samples were used to establish assay cut-offs.

Table 2. Den	ographic	charact	eristics of co	onvales	cence samples of	Cohort 1, grouped
by the time-	points of <b>p</b>	post symj	ptom onset	(PSO) a	t which the sam	ples were taken.

	Convalescent saliva samples (n=74)				
Parameters	< 3 months (n=9)	3-8 months (n=33)	9 months (n=32)		
Gender (F:M)	8:1	23:10	6:26		
Age (years) median (range)	59 (48-67)	49 (20-63)	57 (45-78)		
<ul> <li>Hospitalization status (%)</li> <li>Never hospitalized</li> <li>Hospitalized for only isolation purpose</li> <li>Hospitalized due to COVID-19 symptoms</li> </ul>	66.7 11 22	94 3 3	97 3 0		
Days PSO (Mean   SD)	55   20	120   41	273   11		

medRxiv preprint doi: https://doi.org/10.1101/2021.03.13.21253492; this version posted March 15, 2021. The copyright holder for this preprint **Tablewas Concerned and Salivary antibodic struct Spik to Spik to Spik to Concern and the concern and the concern and the second structure of the secon** 

Convalescence	Serum Ab	Saliv	a IgG	Saliva IgA		
(mo)	SARS CoV-2	Spike-f	NC-C	Spike-f	NC-C	
<3	88.9%	100.0%	88.9%	44.4%	11.1%	
3-8	90.9%	84.8%	60.6%**	6.3%***	3.1%**	
9	96.9%	87.5%	50.0%***	9.7%***	6.5%***	

Note: \*\* and \*\*\* indicate p<0.01 and p<0.0001 respective compared to clinical SARS-Cov-2 serum antibody diagnosis, determined by N-1 Chi-squared test (Campell I, Statistics in medicine, 2007, Richardson JTE, Statistics in medicine, 2011). Ab (antibody). Spike-f (spike foldon), NC-C (nucleocapsid c-terminal chain).

Fig 1.



Fig 2.



Β.



0

٥

**\$**7

Ę

Spike S1

0 9-

		Positive controls (N=74)			ve controls (N=74) Negative controls (N=23*)		
Antigen	Host	Sensitivity [%]	Negative result	Positiv e result	Specificity [%]	Negative result	Positive result
Spike-f S1	HEK CHO	60.8	29	45	100	23	0
Spike-f RBD	HEK HEK	68.9	23	51	100	22	0
Spike-f NC	HEK E.Coli	48.6	38	36	100	23	0
Spike-f NC-C	HEK E.Coli	60.8	29	45	100	23	0
S1 RBD	CHO HEK	68.9	23	51	100	23	0
S1 NC	CHO <i>E.Coli</i>	60.8	29	45	100	23	0
S1 NC-C	CHO <i>E.Coli</i>	60.8	29	45	100	23	0
RBD NC	HEK E.Coli	48.6	38	36	100	23	0
RBD NC-C	HEK E.Coli	60.8	29	45	100	23	0
NC NC-C	E.Coli E.Coli	48.6	38	36	100	23	0

# Supplementary Table 1. Combinations of 2 antigens. Specificity and sensitivity in detecting SARS-CoV-2 IgG in Cohort 1 samples (1-9 months convalescence).

Note. A sample is considered positive when classified positive for both antigens included in the panel.

\* The negative samples included here are Cohort 3 excluded the 12 negative used for cutoff calculation

medRxiv preprint doi: https://doi.org/10.1101/2021.03.13.21253492; this version posted March 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Supplementary Table 2. Combinations of 3 antigens. Specificity and sensitivity in

detecting SARS-CoV-2 IgG in Cohort 1 samples (1-9 months convalescence).

		Positive controls (N=74)			Negative controls (N=23*)		
Antigen	Host	Sensitivity [%]	Negative result	Positiv e result	Specificity [%]	Negative result	Positive result
Spike-f S1 RBD	HEK CHO HEK	70.3	22	52	100	23	0
Spike-f S1 NC	HEK CHO <i>E.Coli</i>	62.2	28	46	100	23	0
Spike-f S1 NC-C	HEK CHO <i>E.Coli</i>	64.9	26	48	100	23	0
S1 RBD NC	CHO HEK <i>E.Coli</i>	62.2	28	46	100	23	0
RBD NC NC-C	HEK E.Coli E.Coli	58.1	31	43	100	23	0
S1 NC NC-C	CHO E.Coli E.Coli	58.1	31	43	100	23	0
Spike-f NC NC-C	HEK E.Coli E.Coli	60.8	29	45	100	23	0
Spike-f RBD NC-C	HEK HEK <i>E.Coli</i>	70.3	22	52	95.7	22	1
S1 RBD NC-C	CHO HEK <i>E.Coli</i>	59.5	30	44	100	23	0
Spike-f RBD NC	HEK HEK <i>E.Coli</i>	67.6	24	50	95.7	22	1

Note. A sample is considered positive when classified positive for two out of three antigens included in the panel.

\* The negative samples included here are Cohort 3 excluded the 12 negative used for cutoff calculation

		Positive controls (N=74)			Negative controls (N=23*)			
Antigen	Host	Sensitivity [%]	Negative result	Positiv e result	Specificity [%]	Negative result	Positive result	
Spike-f*	HEK	16.2	62	12	95.7	22	1	
S1	СНО	5.4	70	4	91.3	21	2	
RBD	HEK	6.8	69	5	91.3	21	2	
NC	E. coli	6.8	69	5	87.0	20	3	
NC-C*	E. coli	5.4	70	4	91.3	21	2	

Supplementary Table 3. Single antigen specificity and sensitivity in detecting SARS-CoV-2 IgA in Cohort 1 samples (1-9 months convalescence).

\* The negative samples included here are Cohort 3 excluded the 12 negative used for cutoff calculation



